SGLT2is are particularly attractive for add-on therapy to insulin in T1DM because they are oral agents that decrease the reabsorption of glucose in the kidney and increase its excretion via the urine, a mechanism that is not dependent of islet cell functionality [14–16, 43, 44]. The gene discussed is INS; the disease is type 1 diabetes mellitus.